LYCA · NASDAQ · Healthcare · $1.4B
$26.40-4.8%vs prev closeclose of 2026-10-30 · not real-time
💰 Net stock buybacks last fiscal year: $3,000 · 0% of market cap
Some axes lack data (–)
A summary of valuation factors — not a buy recommendation. You decide.
| Company | PER | PBR | ROE | Div | Score |
|---|---|---|---|---|---|
| Lycia Therapeutics Inc. | – | – | – | 0.0% | – |
| Nutex Health Inc. | 7.9 | 3.5 | 65% | 0.0% | 72 |
| Omeros Corporation | 15.1 | – | – | 0.0% | 37 |
| Tandem Diabetes Care Inc. | – | 10.2 | -48% | 0.0% | 32 |
| AnaptysBio Inc. | – | 135.6 | – | 0.0% | 38 |
| Pacira BioSciences Inc. | 104.0 | 2.2 | 2% | 0.0% | 56 |
Same sector, nearest by market cap · – = no data (value traps excluded)
Open-market buys & sells by this company's officers & directors (SEC Form 4)
Observational — buy/sell facts only, not a recommendation. Filing dates (the trade was 1–2 business days earlier). Routine comp (option exercises, grants) excluded — discretionary buys/sells only.
The chart (long-term trend, Ichimoku cloud) is for observation only — not a buy or sell signal.
A highlight of the key metrics detailed below.
Top-tier in 0 of 1 evaluated strategies
Ranks within the US market — tap to open that ranking (ranks are per market).
Past returns — they do not guarantee future results.
Color: green = healthy, red = caution (absolute thresholds, value/quality metrics only). Downside vol & Sortino are annualized. Max drawdown = largest drop from a 3-year peak; volatility = 1-year annualized. Price/Graham < 1 = below Graham fair value (profitable, positive-equity names only). RSI < 30 = oversold. For reference only.
A Japanese trend tool. Price above the 'cloud' is supportive; below is weak. A strong uptrend doesn't mean it's cheap — stocks that have run up are usually more expensive.